SCHEMBL4041803

SCHEMBL4041803

CC(C)[C@H](CCC(=O)O)NCc1cc(Oc2ccccc2)ncc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GRN P28799 2/20 0.37
SORT1 Q99523 2/20 0.37
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
FFAR1 O14842 1/20 0.36
ACACB O00763 6/20 0.36
ACACA Q13085 3/20 0.36
CTSA P10619 1/20 0.35
OPRM1 P35372 2/20 0.35
OPRD1 P41143 2/20 0.35
ADAMTS4 O75173 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041816 1.00 LTA4H (0.39) LTA4HNPC1RAB9AALDH1A1GRN
SCHEMBL4038449 0.84 PIN1 (0.36) LTA4HNPC1RAB9AALDH1A1GRN
SCHEMBL4038445 0.84 PIN1 (0.36) LTA4HNPC1RAB9AALDH1A1GRN
SCHEMBL1414178 0.81 S1PR1 (0.39) LTA4HACACBACACA
SCHEMBL1414089 0.81 S1PR1 (0.39) LTA4HACACBACACA
SCHEMBL1414085 0.81 S1PR1 (0.39) LTA4HACACBACACA
SCHEMBL1414377 0.80 EPOR (0.40) LTA4HNPC1RAB9AALDH1A1CYP1A2
SCHEMBL1414542 0.76 NPY5R (0.41) ACACBACACAOPRM1OPRD1OPRK1
SCHEMBL16792623 0.73 SMN1; SMN2 (0.46) LTA4HNPC1RAB9AALDH1A1CYP1A2
SCHEMBL1414384 0.72 GRN (0.36) LTA4HGRNSORT1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531545-B2 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-12 US disclosed
EP-1966198-A1 2-AMINO-3,4-DIHYDRO-PYRIDOÝ3,4-D¨PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-10 EP disclosed
US-20070259898-A1 NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) BAXTER ELLEN E 2007-11-08 US disclosed
WO-2007050612-A1 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259898-A1 NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) BACE2, PSEN2, BACE1 LTA4H 3169/4885NPC1 2408/4885RAB9A 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.